资讯

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at ...
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...
PMLive3 小时
Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults
Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the US Food and Drug Administration (FDA) ...
PharmExec2 天
FDA Approves Expanded Indication for Moderna’s Respiratory Syncytial Virus Vaccine mRESVIA
RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...
The Pharma Letter3 天
FDA nod for Moderna’s RSV Vaccine, mRESVIA for younger adults
US mRNA specialist Moderna today announced that the US Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), ...
AZ Central4 天
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at ...
(NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company’s respiratory syncytial virus (RSV) vaccine, for the prevention of ...
Medical Dialogues3 天
Moderna gets USFDA nod for RSV Vaccine mRESVIA in adults aged 18-59 at increased risk for ...
Cambridge: Moderna, Inc. has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for ...